These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17066647)

  • 21. [Allergy vaccination in Norway].
    Øymar K
    Tidsskr Nor Laegeforen; 2007 Apr; 127(8):1036-8. PubMed ID: 17457388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation.
    Bohle B; Kinaciyan T; Gerstmayr M; Radakovics A; Jahn-Schmid B; Ebner C
    J Allergy Clin Immunol; 2007 Sep; 120(3):707-13. PubMed ID: 17681368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biotherapies of chronic diseases in the inter-war period: from Witte's peptone to Penicillium extract.
    Löwy I
    Stud Hist Philos Biol Biomed Sci; 2005 Dec; 36(4):675-95. PubMed ID: 16337556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient characteristics associated with allergen immunotherapy initiation and adherence.
    Hankin CS; Lockey RF
    J Allergy Clin Immunol; 2011 Jan; 127(1):46-8, 48.e1-3. PubMed ID: 21093021
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy.
    Müller UR; Jutel M; Reimers A; Zumkehr J; Huber C; Kriegel C; Steiner U; Haeberli G; Akdis M; Helbling A; Schnyder B; Blaser K; Akdis C
    J Allergy Clin Immunol; 2008 Nov; 122(5):1001-1007.e4. PubMed ID: 18845330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evaluation of sublingual immunotherapy: an analysis of literature.
    Ciprandi G; Agostinis F; Amoroso S; Ariano R; Barbato A; Bassi M; Cadario G; Campi P; Cardinale F; Romano C; Incorvaia C; Danneo R; Dal Bo S; Di Gioacchino M; Fiocchi A; Galimberti M; Galli E; Giovannini M; La Grutta S; Lombardi C; Marcucci F; Marseglia GL; Mastrandrea F; Minelli M; Nettis E; Novembre E; Ortolani C; Pajno G; Piras PP; Passalacqua G; Patriarca G; Pucci S; Quercia O; Romano A; Schiavino D; Sforza M; Tosca MA; Tripodi S; Zambito M; Puccinelli P; Frati F
    Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():21-6. PubMed ID: 18924463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BSACI Registry for Immunotherapy (BRIT): Providing safe and effective immunotherapy for allergies and urticaria.
    Khan S; Krishna MT; Michaelis LJ; Dawson TC; Marriage D; Thursby-Pelham A; Pur Özyiğit L; Jones C; Regent L; Erlewyn-Lajeunesse M
    Clin Exp Allergy; 2021 Aug; 51(8):985-988. PubMed ID: 34337808
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
    Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
    Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Besredka's desensitization].
    SCHMIDT H; GRABAR L
    Med Klin; 1959 May; 54(18):848-51. PubMed ID: 13666326
    [No Abstract]   [Full Text] [Related]  

  • 30. EAACI 'Standards for practical allergen-specific immunotherapy'.
    Madsen F
    Allergy; 2007 Mar; 62(3):332. PubMed ID: 17298352
    [No Abstract]   [Full Text] [Related]  

  • 31. Reply to the letter by Dr Fleming Madsen (EAACI 'Standards for practical allergen-specific immunotherapy').
    Alvarez-Cuesta E; Bousquet J; Canonica WG; Durham S; Malling HJ; Passalacqua G; Valovirta E
    Allergy; 2008 Jul; 63(7):939-40. PubMed ID: 18588562
    [No Abstract]   [Full Text] [Related]  

  • 32. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce.
    Canonica GW; Baena-Cagnani CE; Bousquet J; Bousquet PJ; Lockey RF; Malling HJ; Passalacqua G; Potter P; Valovirta E
    Allergy; 2007 Mar; 62(3):317-24. PubMed ID: 17298350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to stop the allergy march.
    Lopes Dos Santos JM
    Int J Immunopathol Pharmacol; 2005; 18(4 Suppl):39-40. PubMed ID: 17761107
    [No Abstract]   [Full Text] [Related]  

  • 34. A review of allergen-specific immunotherapy in human and veterinary medicine.
    Loewenstein C; Mueller RS
    Vet Dermatol; 2009 Apr; 20(2):84-98. PubMed ID: 19320877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic and local reactions of bee venom immunotherapy in Iran.
    Bemanian MH; Farhoudi A; Pourpak Z; Gharagozlou M; Movahedi M; Nabavi M; Mozafari H; Mohammadzadeh I; Chavoshzadeh Z; Shirkhoda Z
    Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):203-6. PubMed ID: 18094443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pathology of immunotherapy.
    Hamid Q
    J Allergy Clin Immunol; 2004 Jun; 113(6):1234-7. PubMed ID: 15208611
    [No Abstract]   [Full Text] [Related]  

  • 37. Peptide immunotherapy for allergic diseases.
    Larché M
    Allergy; 2007 Mar; 62(3):325-31. PubMed ID: 17298351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunologic responses to sublingual allergen immunotherapy.
    Akdis M
    Clin Allergy Immunol; 2008; 21():71-86. PubMed ID: 18828499
    [No Abstract]   [Full Text] [Related]  

  • 39. Allergies, allergies.
    Shulman ST
    Pediatr Ann; 2011 Apr; 40(4):177-8. PubMed ID: 21485990
    [No Abstract]   [Full Text] [Related]  

  • 40. [The estimation of treatment of Hymenoptera venoms allergy in children].
    Botulińska E; Piotrowska T; Korol D; Swiebocka E; Hofman J
    Pol Merkur Lekarski; 2006 Sep; 21(123):232-4. PubMed ID: 17163183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.